후성유전 약물 및 진단 기술 시장 예측(2025-2030년)

The epigenetics drugs and diagnostic technologies market is expected to grow at a CAGR of 15.21%, reaching a market size of US$53.345 billion in 2030 from US$26.283 billion in 2025.

Epigenetics diagnosis involves studying changes in genetic, cellular, and physical characteristics without altering the DNA sequence itself. This field serves as an indicator of various changes and plays a vital role in developmental biology. The market for epigenetics drugs and diagnostic technologies is driven by the rising incidence of disorders such as diabetes and obesity, which are linked to inflammatory, metabolic, cardiovascular, and oncological diseases.Moreover, epigenetics is increasingly relevant in diagnosing mental health conditions. Gene expression significantly influences behavior, allowing scientists to explore neurogenetics shaped by environmental factors. This research can enhance understanding of issues like addiction and depression. The growing interest in personal genomics facilitates the collection of individual epigenetic data and DNA sequencing, making personalized medicine more attainable for consumers. As data on DNA increases, epigenetic testing becomes more capable of supporting research and delivering value through tailored medical approaches.

Drivers of the Epigenetics Drugs and Diagnostic Technologies Market:

• Rising Incidence of Cancer Cases: The global increase in cancer cases is a major factor propelling growth in the epigenetics drugs and diagnostic technologies market. According to the American Cancer Society (ACS), there were 20.2 million new cancer cases and 9.7 million cancer deaths worldwide in 2022, with prevalent cancers including breast, lung, prostate, colorectal, and stomach cancers-accounting for nearly 50% of total cases.

Research has shown that cancer progression is often associated with epigenetic abnormalities alongside genetic changes. Epigenetic advancements in cancer research focus on areas such as DNA methylation, histone modifications, nucleosome positioning, and non-coding RNAs like microRNA expression. This has led to the emergence of epigenetic therapies. For example, tests like the Galleri test improve diagnostic capabilities by identifying cancer-specific methylation patterns and extending screening beyond routine methods to include cancers such as pancreatic and ovarian cancer.

Geographical Trends Shaping the Epigenetics Drugs and Diagnostic Technologies Market:

• Rapid Growth in Asia-Pacific: The epigenetics drugs and diagnostic technologies market is segmented into regions including North America, South America, Europe, the Middle East and Africa, and Asia-Pacific. During the forecast period, Asia-Pacific is expected to be the fastest-growing region in this market due to emerging economies like China, Japan, India, and South Korea driving healthcare infrastructure development.

For instance, approximately 4.82 million new cancer cases and 2.57 million cancer deaths were reported in China in 2022. The increasing prevalence of chronic diseases in this region is expected to propel demand for advanced diagnostic technologies related to epigenetics.Meanwhile, North America is projected to maintain a significant share of the market due to its advanced healthcare infrastructure. The high prevalence of neurological disorders contributes to this growth; projections indicate that there will be millions affected by conditions like Alzheimer's disease in the coming years. Furthermore, substantial government investments alongside private sector initiatives are expected to drive continued regional expansion.In summary, the epigenetics drugs and diagnostic technologies market is poised for significant growth driven by rising cancer incidence rates globally, increasing awareness about early diagnosis options, advancements in epigenetic research and technology, supportive governmental initiatives in healthcare investment, and favorable geographical trends-particularly within Asia-Pacific-that enhance this expanding market landscape.

Reasons for buying this report:-

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data & forecasts from 2022 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Epigenetics Drugs And Diagnostic Technologies Market has been segmented as following:

By Drugs

• Histone Deacetylase (HDAC) Inhibitors
• DNA Methyltransferase (DNMT) Inhibitors
• Others

By Technology

• Reagents
• Kits
• Chip Sequencing Kit
• Whole Genomic Amplification Kit
• Bisulfite Conversion Kit
• RNA Sequencing Kit
• Instruments
• Services
• Others

By Application

• Oncology
• Non-oncology
• Inflammatory Diseases
• Metabolic Diseases
• Infectious Diseases
• Cardiovascular Diseases
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Rest of South America
• Europe
• United Kingdom
• Germany
• France
• Italy
• Spain
• Rest of Europe
• Middle East and Africa
• Saudi Arabia
• UAE
• Rest of the Middle East and Africa
• Asia Pacific
• China
• India
• Japan
• South Korea
• Taiwan
• Thailand
• Indonesia
• Rest of Asia-Pacific

TABLE OF CONTENTS

1. INTRODUCTION

• 1.1. Market Overview
• 1.2. Market Definition
• 1.3. Scope of the Study
• 1.4. Market Segmentation
• 1.5. Currency
• 1.6. Assumptions
• 1.7. Base and Forecast Years Timeline
• 1.8. Key benefits for the stakeholders

2. RESEARCH METHODOLOGY

• 2.1. Research Design
• 2.2. Research Process
• 2.3. Data Validation

3. EXECUTIVE SUMMARY

• 3.1. Key Findings
• 3.2. Analyst View

4. MARKET DYNAMICS

• 4.1. Market Drivers
• 4.2. Market Restraints
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Supplier
  • 4.3.2. Bargaining Power of Buyers
  • 4.3.3. Threat of New Entrants
  • 4.3.4. Threat of Substitutes
  • 4.3.5. Competitive Rivalry in the Industry
• 4.4. Industry Value Chain Analysis

5. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY DRUGS

• 5.1. Introduction
• 5.2. Histone Deacetylase (HDAC) Inhibitors
• 5.3. DNA Methyltransferase (DNMT) Inhibitors
• 5.4. Others

6. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY TECHNOLOGY

• 6.1. Introduction
• 6.2. Reagents
• 6.3. Kits
  • 6.3.1. Chip Sequencing Kit
  • 6.3.2. Whole Genomic Amplification Kit
  • 6.3.3. Bisulfite Conversion Kit
  • 6.3.4. RNA Sequencing Kit
• 6.4. Instruments
• 6.5. Services
• 6.6. Others

7. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Oncology
• 7.3. Non-oncology
  • 7.3.1. Inflammatory Diseases
  • 7.3.2. Metabolic Diseases
  • 7.3.3. Infectious Diseases
  • 7.3.4. Cardiovascular Diseases
  • 7.3.5. Others

8. EPIGENETICS DRUGS AND DIAGNOSTIC TECHNOLOGIES MARKET BY GEOGRAPHY

• 8.1. Global Overview
• 8.2. North America
  • 8.2.1. United States
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. South America
  • 8.3.1. Brazil
  • 8.3.2. Argentina
  • 8.3.3. Rest of South America
• 8.4. Europe
  • 8.4.1. United Kingdom
  • 8.4.2. Germany
  • 8.4.3. France
  • 8.4.4. Italy
  • 8.4.5. Spain
  • 8.4.6. Rest of Europe
• 8.5. Middle East and Africa
  • 8.5.1. Saudi Arabia
  • 8.5.2. United Arab Emirates
  • 8.5.3. Rest of the Middle East and Africa
• 8.6. Asia-Pacific
  • 8.6.1. China
  • 8.6.2. India
  • 8.6.3. Japan
  • 8.6.4. South Korea
  • 8.6.5. Taiwan
  • 8.6.6. Thailand
  • 8.6.7. Indonesia
  • 8.6.8. Rest of Asia-Pacific

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Emerging Players and Market Lucrativeness
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Roche Diagnostics
• 10.2. Thermo Fisher Scientific, Inc.
• 10.3. Element Biosciences, Inc.
• 10.4. Dovetail Genomics LLC.
• 10.5. Abcam plc.
• 10.6. Eisai Co., Ltd.
• 10.7. Novartis AG
• 10.8. Cantata Bio
• 10.9. Illumina, Inc.
• 10.10. Promega Corporation
• 10.11. Merck KGaA